Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.
Why it matters
Attributed market update with source link for portfolio context.